Clarient Breathes Life Into Lung Cancer Biz With Applied Genomics Buy

Clarient is expanding its lung cancer business and gaining a pipeline of immunohistochemistry tests for lung, breast and ovarian cancers with its $17.6 million acquisition of Applied Genomics